Evidence map›Paper›PMID 40502805›Full record

ArticleRSC chemical biology2025

Amber Barendrecht, Heleen H C Peeters, Diana Torres-García, M Thierry Shema, Alexi J C Sarris, Shimrit David, Göktuğ Aba, Camille M Le Gall, Martin Wilkovitsch, Martijn Verdoes and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amber BarendrechtDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Heleen H C PeetersDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Diana Torres-GarcíaDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
M Thierry ShemaDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Alexi J C SarrisDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Shimrit DavidDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Göktuğ AbaDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.
Camille M Le GallDepartment of Medical BioSciences, Radboud University Medical Center Nijmegen The Netherlands.
Martin WilkovitschInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 Vienna Austria.
Martijn VerdoesDepartment of Medical BioSciences, Radboud University Medical Center Nijmegen The Netherlands.ORCID https://orcid.org/0000-0001-8753-3528
Hannes MikulaInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 Vienna Austria.
Mark A TravisManchester Collaborative Centre for Inflammation Research, University of Manchester Manchester UK.
Sander I van KasterenDivision of Chemical Biology and Immunology, Leiden Institute of Chemistry, Universiteit Leiden Gorlaeus Laboratory, Einsteinweg 55 Leiden The Netherlands s.i.van.kasteren@chem.leidenuniv.nl.ORCID https://orcid.org/0000-0003-3733-818X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunocytokines have emerged as a promising modality in cancer therapy, capitalizing on the precision of antibodies to deliver cytokines selectively to tumours. Yet, the toxicity of the cytokine portion of these antibody-cytokine constructs remains a major dose-limiting issue. We present a new approach to control cytokine function without affecting binding of the targeting moiety. By modifying the cytokine with

Identifiers

PMID40502805
PMCPMC12151080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.